In the context of unprecedented gene therapy clinical progress and mounting regulatory scrutiny, the inaugural Gene Therapy Analytical Development Summit will unite large pharma an
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh